EGFR and glioblastoma: Han et al. (2015) [240] showed that NK-92- or NKL-derived CAR-NK cells with specificity to both of these antigens displayed a robust increase in cytolytic capacity and IFN-γ secretion, in an EGFR-dependent manner, when co-cultured with GBM cell lines or patient-derived GBM stem cells (GSCs); furthermore, they efficiently suppressed tumor growth, and prolonged the survival of mice with orthotopic GBM xenografts.